AorticLab develops a vascular rehabilitation platform designed to prevent the progression of early-stage abdominal aortic aneurysms (AAAs). Their platform provides tools to stabilize hemodynamics, aiming to halt disease evolution and offer patients a non-surgical treatment option.
Funding
Funding not disclosed
Founders
Product
Problem
Existing guidelines recommend treatment for abdominal aortic aneurysms (AAAs) only when they reach a diameter of 5.5 cm, leaving a large population of diagnosed patients waiting for their aneurysms to progress to this critical size. Current treatments focus on addressing the consequences of the disease rather than preventing its progression, and approximately 15,000 deaths occur annually in the US due to aneurysm rupture.
Solution
Dyverto is developing the Dyve_Mesh device, a minimally invasive endoprosthesis designed to prevent the progression of early-stage AAAs by stabilizing hemodynamics before the aneurysm reaches a critical size. Unlike conventional stent-grafts that exclude the diseased area, Dyverto's device aims to re-establish physiological blood flow while maintaining perfusion of side vessels. The patented technology offers a versatile platform for various cardiovascular and non-cardiovascular applications.
Target Audience
The primary target audience includes vascular surgeons and interventional cardiologists treating patients with early-stage abdominal aortic aneurysms.
Features
- Minimally invasive design for easy navigation through complex anatomies
- Self-expanding Nitinol multilayer construction mimicking the properties of the arterial tunica media
- Designed to eliminate disturbed hemodynamics and re-establish orderly-channeled blood flow
- Maintains uninterrupted perfusion of side vessels
- Platform technology with potential for applications beyond aortic aneurysms